Novartis continues fight to end leprosy
Novartis and the World Health Organization (WHO) announced October 11 that they will extend their collaboration to end leprosy.
New medicines for neglected diseases
Novartis is pioneering medicines for neglected diseases, with institutes focusing solely on diseases for which research was virtually non-existent.
Funding future research
Novartis is leading industry efforts to fill a multi-billion-dollar gap in neglected disease R&D funding.
Novartis & Citizenship
See Novartis Chairman Daniel Vasella, M.D., discuss the values and principles of the United Nations Global Compact on its 10th anniversary.
Living the Global Compact
In a wide-ranging interview, Klaus Leisinger describes how Novartis embodies the principles of the United Nations Global Compact.
Environment & Energy
Keith Saveal, Head of Corporate Health, Safety and Environment & Business Continuity, recounts the evolution of the new UN Environmental Stewardship Strategy.
CIBA VISION creates mobile 'app' to train healthcare providers
Eye care professionals are benefiting from an innovative new iPhone® application offering “anytime, anywhere” access to high-quality educational resources.
April 25 is World Malaria Day
On World Malaria Day, April 25, the international community highlights the campaign to provide effective control of this deadly disease.
Seeking a clearer view of multiple sclerosis
People with multiple sclerosis (MS) face devastating uncertainty, not knowing how the disease will progress or disrupt their daily lives. But scientists are developing new diagnostic tools to aid treatment and ease the unpredictability for patients.
Innovating beyond the Vaccine: VaxTrak puts value in the hands of patients and families
Novartis Vaccines and Diagnostics (NV&D) has developed a way to help parents, families and vaccine consumers track vaccinations using the iPhone®
New products rejuvenate our pharmaceutical portfolio
Just as new medicines are improving the lives of patients fighting serious diseases, success in innovation is rejuvenating the portfolio of Novartis. Recently launched products grew to 16% of net sales for the Pharmaceuticals Division in 2009.
Novartis joins urgent relief efforts for victims of earthquake in Haiti
Novartis joins urgent relief efforts for victims of earthquake in Haiti offering aid in the form of financial support to relief organizations and donations of essential medicines.
Legal team helps navigate through economic crisis
In times of global financial uncertainty, the Novartis legal team takes an innovative approach – serving as both a protective guardian and a proactive partner to the business.
The information in the feature stories on these pages was factually accurate on the date of publication. These feature stories remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.